PLATE 04 · THE FOLLICLE
Copper Peptide Hair Growth: GHK-Cu Follicle Research
The 45-patient hair-count trial, the angiogenic and anagen mechanism, and the question of whether copper regrows hair at all — pressed plate by plate, with the combination-formulation caveat marked.
What copper peptide hair growth research shows
Copper peptide hair growth research has one strong controlled human signal and a wider base of preclinical follicle biology. In a 6-month trial of 45 men with androgenetic alopecia (Norwood-Hamilton II-V), a topical complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide (ALAVAX) increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 for placebo (p<0.05), with no adverse events in any group [4]. That is the strongest copper peptide hair growth result in the peer-reviewed record — and it carries a caveat pressed beside it: ALAVAX is a combination of 5-ALA and GHK, not pure GHK-Cu, so the trial is a strong but qualified signal. The lower 50 mg/mL concentration produced the larger hair-count gain, a non-linear result worth noting rather than smoothing over.
The mechanism is non-androgenic, which sets copper peptides apart from the dominant hair-loss research targets. Tissue-remodeling reviews attribute copper-peptide follicle effects to VEGF and FGF-2 upregulation in dermal fibroblasts, microvascular angiogenesis around the follicle, and dermal-papilla support rather than hormone blockade [6]. GHK-Cu is not established as a 5-alpha-reductase inhibitor; its follicle activity in the research operates through angiogenesis and anagen-phase support.
Follicle biology explains why an angiogenic signal would matter. The hair follicle cycles through a growth phase (anagen), a regression phase, and a resting phase (telogen), and the dermal papilla at its base — fed by a dense microvascular network — governs that cycle. Copper-peptide research reports extended anagen and faster re-entry from telogen, alongside dermal-papilla proliferation and reduced apoptosis in study models [6]. A peptide that raises VEGF and FGF-2 and supports follicular microvasculature is, mechanistically, acting on exactly the tissue the hair cycle depends on. The strength of that mechanistic story is also its limitation here: most of it is preclinical, and the one controlled human trial tested a combination, not the isolated copper tripeptide.